WHAT THE FIORINA GROUP IS ALL ABOUT
The Fiorina Group has been working on diabetes mellitus type 1 for more than 10 years. In particular, it has published several scientific papers both on the study of immune response and its modulation in patients with diabetes, acute and chronic complications of type 1 diabetes, the role of stem cells in diabetes, islet transplantation in preclinical mouse models and in clinical trials in patients. The projects developed by the group are typically translational in nature, where basic research often meets clinical application, making the results obtained of extreme interest to the scientific community.
THE GROUP CURRENTLY CENTERS ITS INTEREST ON THE FOLLOWING TOPICS:
- Development of a vaccine therapy for type 1 diabetes
- Defining the mechanisms of pancreatic regeneration
- New strategies to modulate the microbiome in type 1 diabetes
- The study of circulating betatoxins
- The enterostamine 2.0
- Immunological characterization of IPS-beta derived cells


SERVICE OFFERED
The Fiorina Group taking advantage of its extensive experience in the study of type 1 diabetes offers the following services:
- Basic immunophenotypic characterization of Immune System cells (T lymphocytes, B lymphocytes and macrophages)
- Functional characterization of immune response (quantification of immune response to stimuli, compounds, proteins, peptides by Elispot assay)
- Transcriptome profiling by array
- Cytokines profiling, Analysis of circulating soluble factors (Bio-Plex 200)
- Expression studies by confocal microscopy

TEAM
The team consists of Professor Fiorina and two researchers, Dr. Francesca D’Addio and Dr. Moufida Ben Nasr, a Senior Scientist/Lab manager Dr. Cristian Loretelli and five young post-docs.